The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2044
Abstract: Felcisetrag (formerly known as TAK‐954) is a selective serotonin receptor agonist under investigation for use in patients with postoperative gastrointestinal dysfunction. The safety, tolerability, and pharmacokinetics (PK) of intravenous (i.v.) felcisetrag have been studied, but… read more here.
Keywords: effect hepatic; hepatic impairment; time; felcisetrag ... See more keywords